Ever since the start of the COVID-19 pandemic, we all knew that children are at the lowest risk of becoming severely ill because of the coronavirus. However, there’s a bit of conundrum regarding how the immune response of the little ones will react when it comes to COVID vaccines.
To solve the lingering mystery, Oxford University plans to extend its COVID-19 vaccine study, according to abcNEWS. The study will include children, and some of them are even 6-years old.
Phase 2 trial is on its way
The phase 2 trial will unveil if the kids have a good enough immune system to COVID vaccines, and it’s funded by AstraZeneca and the National Institute for Health Research (NIHR). Three hundred volunteers will be involved in the new study.
Andrew Pollard, who is a professor of paedriatic infection and immunity and also the chief investigator on the Oxford vaccine trial, declared:
These new trials will extend our understanding of control of SARS-CoV2 to younger age groups.
Rinn Song, who’s a paediatrician and clinician-scientist for the Oxford Vaccine Group, stated:
The COVID-19 pandemic has had a profound negative impact on the education, social development and emotional well-being of children and adolescents, beyond illness and rare severe disease presentations. It is therefore important to collect data on the safety and the immune response to our coronavirus vaccine in these age groups, so that they could potentially benefit from inclusion in vaccination programs in the near future.
The COVID-19 pandemic continues to kill thousands of people every day on the planet, as worldometers.info reports that there are over 108 million infections throughout the globe and more than 2.3 million deaths. The most affected country by the coronavirus remains the USA, with over 28 million infections and a death toll that surpasses 493,000 people.